Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab

Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab

Objective: To describe a case of sustained disease control for over five years in a patient with recurrent, advanced endometrial cancer treated with lenvatinib and pembrolizumab, despite significant treatment-related toxicities. Methods: We present a 49-year-old patient with grade 3, stage IVB endom...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sahana Somasegar, Becky Sousa MSN, Arati Jairam-Thodla, Oliver Dorigo
Format:	Article
Language:	English
Published:	Elsevier 2025-04-01
Series:	Gynecologic Oncology Reports
Subjects:	Advanced endometrial cancer Lenvatinib Pembrolizumab Long-term disease control Treatment-related toxicities
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352578925000426
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer
by: Shao-Jing Wang, et al.
Published: (2025-03-01)

The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01)

Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
by: E. A. Khachaturyan, et al.
Published: (2025-05-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01)

Efficacy and safety of combination therapy with lenvatinib and pembrolizumab in elderly patients with advanced endometrial cancer
by: M. V. Volkonskiy, et al.
Published: (2025-05-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2025-03-01)

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01)

Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
by: Shimpei Yamashita, et al.
Published: (2025-05-01)

Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01)

Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report
by: Shinkuro Yamamoto, et al.
Published: (2025-09-01)

Efficient sequence of therapy for advanced and metastatic endometrial cancer
by: A. A. Rumyantsev
Published: (2022-09-01)

Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response
by: Guanlin Dai, et al.
Published: (2025-08-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

A Computational Study of Efficient Combinations of FDA-Approved Drugs and Dietary Supplements in Endometrial Cancer
by: Madhurima Mondal, et al.
Published: (2024-01-01)

Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis
by: Xinqiang Zhao, et al.
Published: (2025-06-01)

Clinical and morphological features in patients with advanced endometrial cancer treated with immunotargeting therapy
by: L. A. Kolomiets, et al.
Published: (2023-08-01)

Influence of immune targeted therapy on immune system parameters in patients with endometrial cancer
by: M. N. Stakheyeva, et al.
Published: (2025-05-01)

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
by: Camillo Porta, et al.
Published: (2025-05-01)

Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
by: Ilya Tsimafeyeu, et al.
Published: (2025-04-01)

Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus
by: A. S. Tyulyandina, et al.
Published: (2023-05-01)

Expanding therapeutic opportunities for progressive uterine cancer: clinical experience
by: A. G. Kedrova, et al.
Published: (2022-05-01)

Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis
by: Biqiong Pan, et al.
Published: (2025-02-01)

Acute vascular and cardiac effects of lenvatinib in mice
by: Dustin N. Krüger, et al.
Published: (2025-02-01)

Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database
by: Huiping Zhang, et al.
Published: (2025-08-01)

Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report
by: Tsuneo Imai, et al.
Published: (2022-01-01)

Pembrolizumab: The nut cracker
by: Gangothri Selvarajan
Published: (2020-01-01)

Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases
by: Xiaolong Liu, et al.
Published: (2025-12-01)

Optic neuritis induced by Pembrolizumab treatment for recurrent vulvar cancer
by: Ariel Cohen, et al.
Published: (2025-06-01)

Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report
by: Alessia Lancianese, et al.
Published: (2025-06-01)

Acquired lipodystrophy following use of pembrolizumab
by: Maya Weitzen, et al.
Published: (2024-12-01)

A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers
by: Stéphanie L. Gaillard, et al.
Published: (2025-06-01)

Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials
by: Nikolas Naleid, et al.
Published: (2025-01-01)

Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression
by: Vesna Ćeriman Krstić, et al.
Published: (2025-04-01)

Emerging Role of Lenvatinib in Treating Platinum-Refractory Head and Neck Cancer in Resource-Limited Settings
by: Avinash Khadela, et al.

Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
by: T. T. Andabekov, et al.
Published: (2019-07-01)

Long sustained response during second-line pembrolizumab plus lenvatinib in a patient with recurrent endometrial carcinoma: a case report
by: Laura Fabbri, et al.
Published: (2025-06-01)

Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation
by: Yuan Yuan, et al.
Published: (2025-12-01)